Corindus Vascular Robotics (NYSE:CVRS) released post-market findings from the Precision registry study of its CorPath 200 system used during percutaneous coronary interventions, touting high clinical and technical success rates.

Data from the registry study was presented at the 2017 Society for Cardiovascular Angiography and Interventions Scientific Sessions last Friday, the Waltham, Mass.-based company said.

The Precision post-market registry study aimed to explore the effectiveness of the Corindus’ CorPath 200 system during routine use in PCI procedures. The study examined the use of the device in 754 patients treating an aggregate of 949 lesions, with transradial access used in 452 cases and transfemoral access in 298.

Results from the study indicated an 88.6% technical success rate and 98.9% clinical success rate in transradial access cases, with an 82.4% technical success rate and 94.9% clinical success rate for transfemoral access procedures.

“The selection of this study as a late breaking clinical trial at SCAI 2017 is a testament to the significance robotics will have in invasive cardiology. My early experience with the CorPath 200 System demonstrated feasibility, safety and procedural effectiveness of robotic PCI to be comparable to the manual approach, even in complex and radial access PCI. I am excited to lead the PRECISION GRX Registry to further demonstrate the applicability and value of CorPath GRX in complex and radial cases,” principal investigator Dr. Ehtisham Mahmud of the UC San Diego School of Medicine said in a press release.

The company said it is launching another post-market registry, the Precision GRX study, to surveil its 2nd generation CorPath GRX system, with Dr. Mahmud working as principal investigator.